US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SpyGlass Pharma, Inc.

26.32

+0.05500.21%

Volume:13.21K

Turnover:350.64K

Market Cap:876.75M

PE:-15.70

High:26.68

Open:26.45

Low:26.16

Close:26.26

52wk High:32.44

52wk Low:17.06

Shares:33.32M

Float Shares:10.78M

Volume Ratio:1.40

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6760

EPS(LYR):-17.9825

ROE:-67.71%

ROA:-37.23%

PB:3.77

PE(LYR):-1.46

Loading ...

Overview Company News Filings

Spyglass Pharma Appoints Mike Pinder as Vice President, Marketing

THOMSON REUTERS

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Fiserv (FISV)

SpyGlass Pharma management joins Stifel virtual ophthalmology forum fireside chat

SpyGlass Pharma to Participate in Upcoming Investor Conferences

Jefferies Sticks to Its Buy Rating for SpyGlass Pharma (SGP)

Spyglass Pharma Inc - Bim-Iol System Phase 3 Trial Enrollment Expected to Complete in 2027

THOMSON REUTERS

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

Spyglass Pharma publishes deck on long-acting intraocular drug delivery for glaucoma patients

SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate

Benzinga Earnings

Spyglass Pharma Q1 FY26 net loss widens 57% to $13.82 million

Press Release: SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Stockland Releases Operational Update for Third Quarter 2026

Spyglass Pharma publishes corporate presentation on long-acting intraocular drug delivery for glaucoma

Keppel DC REIT plans AEI for KDC SGP 1

The Edge Singapore

Stockland Reports Lapse of 252,523 Performance Rights

Analysts Offer Insights on NA Companies: BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (Nasdaq: SGP)

SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY

Benzinga Earnings

Spyglass Pharma Inc: Q4 Net Loss $5.72 per Basic and Diluted Share

THOMSON REUTERS

SpyGlass Pharma FY2025 net loss widened 36.64% to $39.9 million; loss per share widened to $17.98

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SGP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SGP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","market":"US","secType":"STK","nameCN":"SpyGlass Pharma, Inc.","latestPrice":26.315,"timestamp":1787667570384,"preClose":26.26,"halted":0,"volume":13210,"delay":0,"changeRate":0.0020944402132520835,"floatShares":10781300,"shares":33317414,"eps":-1.676,"marketStatus":"Trading","change":0.055,"latestTime":"08-25 10:19:39 EDT","open":26.45,"high":26.68,"low":26.16,"amount":350639.56895,"amplitude":0.019802,"askPrice":26.6,"askSize":100,"bidPrice":26.18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.676,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":26.26,"postHourTrading":{"tag":"盘后","latestPrice":26.26,"preClose":26.26,"latestTime":"19:30 EDT","volume":402,"amount":10556.52,"timestamp":1787614203623,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.401237},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","floatShares":10781300,"roa":"-37.23%","roe":"-67.71%","lyrEps":-17.982467,"volumeRatio":1.401237,"shares":33317414,"dividePrice":0,"high":26.68,"amplitude":0.019802,"preClose":26.26,"low":26.16,"week52Low":17.06,"pbRate":"3.77","week52High":32.44,"institutionHeld":0,"latestPrice":26.315,"eps":-1.676,"divideRate":0,"volume":13210,"delay":0,"ttmEps":-1.676,"open":26.45,"prevYearClose":16,"prevWeekClose":26.51,"prevMonthClose":22.53,"prevQuarterClose":22.26,"fiveDayClose":25.84,"twentyDayClose":21.62,"sixtyDayClose":19.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SGP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"SGP","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2026-05-14","symbol":"SGP","fiscalQuarterEnding":"2026/03","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.69},{"market":"US","date":"2026-03-26","symbol":"SGP","fiscalQuarterEnding":"2025/12","expectedEps":-6.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-5.72}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SGP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SGP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1786939200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SGP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SGP","date":"2026-08-21","current":-15.668258,"percent":0.606061,"low":-21.652266,"twenty":-19.814976,"median":-16.231773,"eighty":-15.105016,"high":-14.017506,"avg":-17.049793,"sd":2.189594,"marketCap":877340489},"quantilePoints":[{"date":"2026-04-02","current":-20.423828,"twenty":-20.915203,"median":-19.976743,"eighty":-19.275615,"marketCap":814277598},{"date":"2026-04-10","current":-17.791054,"twenty":-19.887327,"median":-18.894548,"eighty":-18.2941,"marketCap":709311539},{"date":"2026-04-17","current":-20.985395,"twenty":-20.628232,"median":-19.259819,"eighty":-18.2941,"marketCap":836666721},{"date":"2026-04-24","current":-19.811622,"twenty":-20.628232,"median":-20.01284,"eighty":-18.750195,"marketCap":789869541},{"date":"2026-05-01","current":-19.233119,"twenty":-20.557806,"median":-19.76551,"eighty":-18.750195,"marketCap":766805217},{"date":"2026-05-08","current":-21.287223,"twenty":-20.628232,"median":-20.01284,"eighty":-18.869002,"marketCap":848700282},{"date":"2026-05-15","current":-20.348204,"twenty":-20.557806,"median":-19.991879,"eighty":-18.951807,"marketCap":811262538},{"date":"2026-05-22","current":-16.428664,"twenty":-20.542715,"median":-19.82839,"eighty":-18.248826,"marketCap":737055581},{"date":"2026-05-29","current":-16.634049,"twenty":-20.51924,"median":-19.719397,"eighty":-17.334564,"marketCap":663182890},{"date":"2026-06-05","current":-16.323837,"twenty":-20.485703,"median":-19.406541,"eighty":-16.365768,"marketCap":650815064},{"date":"2026-06-12","current":-15.166832,"twenty":-20.465581,"median":-18.98998,"eighty":-15.765344,"marketCap":604686416},{"date":"2026-06-18","current":-15.259057,"twenty":-20.45723,"median":-18.830682,"eighty":-15.591067,"marketCap":608363337},{"date":"2026-06-26","current":-14.017506,"twenty":-20.408703,"median":-18.172531,"eighty":-15.533886,"marketCap":628881407},{"date":"2026-07-02","current":-14.509349,"twenty":-20.348204,"median":-17.531147,"eighty":-15.527136,"marketCap":650947421},{"date":"2026-07-10","current":-14.956478,"twenty":-20.239211,"median":-16.634049,"eighty":-15.359666,"marketCap":671007434},{"date":"2026-07-17","current":-15.470677,"twenty":-20.105065,"median":-16.579363,"eighty":-15.259057,"marketCap":694076449},{"date":"2026-07-24","current":-15.560103,"twenty":-20.01284,"median":-16.428664,"eighty":-15.247112,"marketCap":698088452},{"date":"2026-07-31","current":-16.9313,"twenty":-19.979303,"median":-16.327675,"eighty":-15.249961,"marketCap":759605825},{"date":"2026-08-07","current":-14.762377,"twenty":-19.930676,"median":-16.460092,"eighty":-15.249961,"marketCap":827475536},{"date":"2026-08-14","current":-15.019457,"twenty":-19.846835,"median":-16.323837,"eighty":-15.098224,"marketCap":841885631},{"date":"2026-08-21","current":-15.651981,"twenty":-19.814976,"median":-16.231773,"eighty":-15.105016,"marketCap":877340489}],"updateTime":1787646515288},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SGP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640910404","title":"Spyglass Pharma Appoints Mike Pinder as Vice President, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910404?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA1NHWQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640948859","title":"SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640948859","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640948859?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":"ALISO VIEJO, Calif., June  02, 2026  (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305080/0/en/SpyGlass-Pharma-Appoints-Mike-Pinder-as-Vice-President-Marketing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639383622","title":"Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Fiserv (FISV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639383622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639383622?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:40","pubTimestamp":1780054816,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on SpyGlass Pharma (SGP) and Fiserv (FISV). SpyGlass Pharma (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spyglass-pharma-sgp-and-fiserv-fisv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spyglass-pharma-sgp-and-fiserv-fisv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0130102774.USD","BK4106","LU0648001328.SGD","LU1923622291.USD","LU0130103400.USD","LU0980610538.SGD","LU1861220207.SGD","BK4007","NA","LU2125909916.SGD","SGP","LU0648000940.SGD","LU1861217088.USD","LU2125909759.SGD","LU1823568750.SGD","LU0208291251.USD","LU0320765489.SGD","LU0354030438.USD","BK4141","LU1201861249.SGD","BK4585","BK4588","BK4227","LU0354030511.USD","LU0070302665.USD","LU1201861165.SGD","LU1046421795.USD","FISV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333415","title":"SpyGlass Pharma management joins Stifel virtual ophthalmology forum fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333415?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364824,"startTime":"0","endTime":"0","summary":"Spyglass Pharma executive management will take part in investor conference sessions on May 26, June 4, June 10.Events include fireside chats at the Stifel 2026 Virtual Ophthalmology Forum on May 26 and the Jefferies Global Healthcare Conference on June 4.A corporate presentation is scheduled for the Goldman Sachs 47th Annual Global Healthcare Conference on June 10.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL7FFqJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BFXG1179.USD","IE00BGHQF748.EUR","LU0251131958.USD","LU1868837300.USD","LU2471134796.USD","BK4550","BK4007","BK4552","LU1894683348.USD","IE0004091025.USD","SG9999014005.SGD","LU2750360997.AUD","LU0096364046.USD","LU0251142724.SGD","IE0004086264.USD","BK4504","SG9999014021.USD","LU1804176565.USD","LU2237443622.USD","LU2471134523.USD","LU0314104364.USD","LU1791807156.HKD","LU1868836757.USD","LU1868836914.USD","LU1668664300.SGD","LU0942090050.USD","LU1894683264.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","LU2471134952.CNY","BK4585","LU2237443465.HKD","SGP","IE00BKPKM429.USD","LU2237443549.SGD","IE0034235188.USD","LU2237443978.SGD","LU2210149790.SGD","LU2237438978.USD","LU2750360641.GBP","SG9999014039.USD","LU0106831901.USD","NDAQ","BK4112","BK4127","IE00B19Z3B42.SGD","LU0061475181.USD","GSX","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333066","title":"SpyGlass Pharma to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333066","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333066?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"ALISO VIEJO, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299275/0/en/SpyGlass-Pharma-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636586310","title":"Jefferies Sticks to Its Buy Rating for SpyGlass Pharma (SGP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636586310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636586310?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:55","pubTimestamp":1779209724,"startTime":"0","endTime":"0","summary":"Jefferies analyst Dennis Ding maintained a Buy rating on SpyGlass Pharma today and set a price target of $62.00. Ding covers the Healthcare sector,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636733940","title":"Spyglass Pharma Inc - Bim-Iol System Phase 3 Trial Enrollment Expected to Complete in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2636733940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636733940?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:04","pubTimestamp":1779105868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073386","title":"SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073386","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073386?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":"Additional supportive reimbursement pathway for surgeons may enhance patient access to the BIM-IOL System upon potential commercializationALISO VIEJO, Calif., May  18, 2026  (GLOBE NEWSWIRE) -- SpyGla","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3296580/0/en/SpyGlass-Pharma-Announces-New-Add-on-Category-III-CPT-Code-for-Its-Innovative-BIM-IOL-System.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMA","III","SGP","CPT","BK4215","BK4588","BK4007","BK4134","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635608713","title":"Spyglass Pharma publishes deck on long-acting intraocular drug delivery for glaucoma patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608713","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608713?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:10","pubTimestamp":1778850620,"startTime":"0","endTime":"0","summary":"Spyglass Pharma outlined Phase 3 pivotal trials underway for BIM-IOL System, an intraocular lens drug-delivery product designed to provide about 3 years of bimatoprost therapy for open-angle glaucoma or ocular hypertension at time of routine cataract surgery.First-in-human feasibility data showed 95% of patients off topical IOP-lowering therapy at 36 months, with 37% mean IOP reduction across doses.Phase 1/2 results with intended commercial dose of 78 mcg showed 98% of patients off topical IOP-lowering therapy at 12 months, with 34% mean IOP reduction.Company pegged BIM-IOL System addressable U.S. market at about USD 13 billion, citing an estimated 1,000,000 U.S. glaucoma or ocular hypertension patients projected to undergo cataract surgery in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL2y9lT1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635299137","title":"SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635299137","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635299137?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:04","pubTimestamp":1778792661,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 64.29 percent. This is a 82.58 percent increase over losses of $(3.96) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52583721/spyglass-pharma-q1-eps-0-69-misses-0-42-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635838726","title":"Spyglass Pharma Q1 FY26 net loss widens 57% to $13.82 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635838726","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635838726?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:33","pubTimestamp":1778790805,"startTime":"0","endTime":"0","summary":"Spyglass Pharma posted a net loss of USD 13.82 million, widening 57% year over year, as operating loss widened to USD 15.41 million.Research and development expense rose 41% to USD 8.54 million, while general and administrative costs more than doubled to USD 6.87 million.Interest income climbed to USD 1.59 million from USD 126,000 a year earlier.Cash and cash equivalents and short-term investments totaled USD 251 million as of March 31, 2026, following USD 157.76 million of net cash provided by financing activities tied mainly to IPO proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retriev","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL4Pvlvr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723166","title":"Press Release: SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723166?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"-- Enrollment remains on track in the registrational Phase 3 trials of the. Bimatoprost Drug Pad-IOL System , with completion of. -- Topline 12-month data from the BIM-IOL System Phase 1/2 trial. demonstrated elimination of IOP-lowering topical eye drops for 98% of. trial participants and 34% mean intraocular pressure  reduction from. baseline at the intended commercial dose of 78-mcg, and all patients. achieving best-corrected distance visual acuity  on par with. state-of-the-art monofocal IOLs in the control group at 20/32 or better. -- Bimatoprost-Drug Ring System  first-in-human trial is on track. to start in the second half of 2026.-- Cash, cash equivalents and short-term investments of $251.0 million on. March 31, 2026, are expected to fund planned operations through 2028.ALISO VIEJO, Calif., May 14, 2026  -- SpyGlass Pharma, Inc.  , a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the first quarter ended March 31, 2026.F","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRS","IE00B19Z4B17.USD","BK4007","BK4187","SGP","IE00B66KJ199.SGD","IE0031619046.USD","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557656","title":"Stockland Releases Operational Update for Third Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631557656?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:21","pubTimestamp":1777508517,"startTime":"0","endTime":"0","summary":"The latest update is out from Stockland ( ($AU:SGP) ). Stockland has released its operational update for the third quarter of the 2026 financial ye...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stockland-releases-operational-update-for-third-quarter-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stockland-releases-operational-update-for-third-quarter-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631544927","title":"Spyglass Pharma publishes corporate presentation on long-acting intraocular drug delivery for glaucoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2631544927","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631544927?lang=en_us&edition=fundamental","pubTime":"2026-04-30 01:08","pubTimestamp":1777482507,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma outlined lead BIM-IOL System, designed to deliver at least 3 years of bimatoprost therapy for open-angle glaucoma or ocular hypertension during routine cataract surgery.First-in-human feasibility trial showed 95% of patients off topical IOP-lowering drops at 36 months.Study also reported 37% mean IOP reduction at 36 months across all doses.Phase 1/2 results for intended commercial dose of 78 mcg showed 98% of patients off topical therapy at 12 months.Cash, cash equivalents, short-term investments totaled $107.4 million as of Dec. 31, 2025, before $172.5 million gross IPO proceeds closed Feb. 9, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLbHVQxD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628246996","title":"Keppel DC REIT plans AEI for KDC SGP 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2628246996","media":"The Edge Singapore ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628246996?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:55","pubTimestamp":1776297328,"startTime":"0","endTime":"0","summary":"Keppel DC REIT mulls transformational AEIs for KDC SGP 1 following 1Q2026 business updates where DPU rose by 13.2% y-o-y ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/capital/brokers-calls/keppel-dc-reit-plans-aei-kdc-sgp-1?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/capital/brokers-calls/keppel-dc-reit-plans-aei-kdc-sgp-1?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["LU0971096721.USD","LU1244550221.USD","SG9999013486.USD","8C8U.SI","LU1244550577.SGD","BK4024","LU1989772923.USD","SG9999001135.SGD","LU1162221912.USD","LU1363072403.SGD","IE00BKVL7J92.USD","SG9999008742.SGD","LU0557290698.USD","SG9999002950.SGD","LU0912757837.SGD","LU2417539215.USD","LU0516422952.EUR","LU0158827781.USD","LU0516423091.SGD","BN4.SI","LU0516422440.USD","SGP","LU0006306889.USD","LU2238330802.EUR","LU1244550494.USD","LU2236285917.USD","DC","LU2087589342.USD","LU2271345857.HKD","LU0158827948.USD","SG9999000475.SGD","SG9999014484.SGD","LU1242518857.USD","BK6523","LU0225283273.USD","LU1720051108.HKD","REIT","SGXZ24219693.SGD","SG9999004220.SGD","LU0314104364.USD","LU1732799900.SGD","LU0106261372.USD","LU0882574139.USD","LU2456880835.USD","SGXZ43160589.SGD","LU1791710582.SGD","LU2089284900.SGD","AEI","CFA.SI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420450","title":"Stockland Reports Lapse of 252,523 Performance Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420450","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420450?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:03","pubTimestamp":1776207798,"startTime":"0","endTime":"0","summary":"Stockland ( ($AU:SGP) ) has issued an announcement. Stockland has reported a change in its issued capital, notifying the market of the cessation of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stockland-reports-lapse-of-252523-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stockland-reports-lapse-of-252523-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622564822","title":"Analysts Offer Insights on NA Companies: BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (Nasdaq: SGP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622564822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622564822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:10","pubTimestamp":1774617046,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (SGP...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-bitgo-holdings-inc-class-a-btgo-and-spyglass-pharma-nasdaq-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-bitgo-holdings-inc-class-a-btgo-and-spyglass-pharma-nasdaq-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP","NA","BK4127","BTGO","BK4141","BK4007","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896078","title":"SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896078","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896078?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:21","pubTimestamp":1774556467,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent decrease over losses of $(4.58) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51495858/spyglass-pharma-q4-eps-5-72-down-from-4-58-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622964308","title":"Spyglass Pharma Inc: Q4 Net Loss $5.72 per Basic and Diluted Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2622964308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622964308?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555762,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E128:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896499","title":"SpyGlass Pharma FY2025 net loss widened 36.64% to $39.9 million; loss per share widened to $17.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896499?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555760,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma filed a Form 8-K reporting fourth-quarter and full-year 2025 results and a corporate update, including the completion of its IPO raising USD 172.5 million in gross proceeds and a Nasdaq listing.Cash, cash equivalents and short-term investments were USD 107.4 million at year-end 2025, and the company said its cash position including IPO proceeds is expected to fund planned operations through 2028.R&D expense rose 35.09% to USD 7.7 million in Q4 and increased 46% to USD 29.2 million for FY 2025, driven by hiring clinical and research personnel and initiating registrational Phase 3 trials for the BIM-IOL System.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8gZ4Dk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":57,"code":"91000000","status":"200"}]}}